CR-01 · Clinician Review
Clinician reviewSynthetic demo dataTarget state: Any deteriorating state · onset 5 d · prior: symptom −12%, persistence +15%, tolerance +10%Simulate for P-01454
For P-01454
Eligible at 75% confidence. Among the 284 most similar trajectories: 9 accepted, 100% improved, mean effect −18%.
What it is
Clinician review: LIFE OS assembles a one-page summary (trajectory, divergence, theories, what was tried) and the investigator sees the patient within 72 hours. Autonomous guidance is suspended until the review.
How it works
An escalation, not a treatment. Used when the state is fragile, when evidence for any self-managed protocol is thin, or when pessimism and energy trackers indicate that a human conversation is the intervention.
What the patient does, day by day
| Day 0 | 🏥 | Summary generated LIFE OS insight + Human Model page exported for the clinician. |
| Day 1–3 | 🏥 | Clinician visit Dose review, anti-emetic review, labs; decision recorded in LIFE OS. |
| After | ✓ | Clinician plan in the companion Whatever the clinician decides becomes the daily content. |
Delivery
- Owner
- Investigator
- Channel
- Site visit or telehealth; summary attached
- Duration
- 3 days
- Touchpoints
- One visit; follow-up plan written by the clinician
- Cost
- ≈ €300 per patient (visit)
Monitoring
- · Whatever the clinician orders
Stop rules
- · n/a — the clinician decides
Contraindications
- none recorded
Evidence in NBL-101
11 accepted · 100% improved · mean effect −18%By biology segment
| FUT2 non-secretor | n 6 | 100% |
| IL6 high-expression variant | n 6 | 100% |
| Low butyrate capacity | n 5 | 100% |
| Low microbial diversity | n 8 | 100% |
By trajectory cluster
| LT | n 9 | 100% |
Works best when
- · Toxicity ≥ 55 or discontinuation risk ≥ 75 %
- · Pessimism > 7 with energy < 3
- · No protocol clears the evidence bar
Works poorly when
- · Used for patients a companion protocol would have handled (site burden)
What the model has learned about it
No learned rule yet for CR-01. Run learning after campaign results.
Campaigns using it
None yet. 232 patients look eligible right now.